
DigiM Solution is a company specializing in microstructure science and digital twin technology for drug product development. They provide end-to-end microstructure contract research organization (CRO) and software solutions that integrate advanced microscopic analysis, AI image processing, and computational physics to understand and predict drug product properties and performance. Their cloud-based platform, digiM I2S, supports the entire lifecycle of image data and simulation, enabling pharmaceutical partners to accelerate therapeutic programs and reduce development costs. DigiM collaborates closely with leading innovators, generic drug developers, and regulatory bodies like the U.S. FDA, contributing to regulatory filings and pharmaceutical quality assessment. The company has supported over 95% of programs, digitized 981 formulations, and partnered with 22 pharmaceutical companies, positioning itself as a leader in microstructure science for drug development.

DigiM Solution is a company specializing in microstructure science and digital twin technology for drug product development. They provide end-to-end microstructure contract research organization (CRO) and software solutions that integrate advanced microscopic analysis, AI image processing, and computational physics to understand and predict drug product properties and performance. Their cloud-based platform, digiM I2S, supports the entire lifecycle of image data and simulation, enabling pharmaceutical partners to accelerate therapeutic programs and reduce development costs. DigiM collaborates closely with leading innovators, generic drug developers, and regulatory bodies like the U.S. FDA, contributing to regulatory filings and pharmaceutical quality assessment. The company has supported over 95% of programs, digitized 981 formulations, and partnered with 22 pharmaceutical companies, positioning itself as a leader in microstructure science for drug development.